|
Details of clinico-pathologic data and expression of Mcm2 in diffuse large B-cell lymphomas |
|||
| Variable |
Categorisation |
n analysable |
% |
|
|
|||
| Clinico-pathologic data: |
|||
| Age at diagnosis |
|||
| median 67 years (interquartile range 54–75 years) |
|||
| <65 years |
69 |
43.1 |
|
| ≥65 years |
91 |
56.9 |
|
| Gender |
|||
| male |
97 |
53.3 |
|
| female |
85 |
46.7 |
|
| Ann Arbor stage |
|||
| 1 |
27 |
17.3 |
|
| 2 |
50 |
32.1 |
|
| 3 |
34 |
21.8 |
|
| 4 |
45 |
28.8 |
|
| International prognostic index (IPI) |
|||
| 0 |
2 |
1.3 |
|
| 1 |
66 |
43.4 |
|
| 2 |
29 |
19.1 |
|
| 3 |
32 |
21.1 |
|
| 4 |
23 |
15.1 |
|
| Bone marrow involvement |
|||
| yes |
44 |
28.6 |
|
| no |
110 |
71.4 |
|
| Extranodal involvement |
|||
| yes |
54 |
35.8 |
|
| no |
97 |
64.2 |
|
| Bulky disease |
|||
| yes |
94 |
64.4 |
|
| no |
52 |
35.6 |
|
| Chemotherapy |
|||
| no therapy |
7 |
4.6 |
|
| CHOP |
69 |
45.1 |
|
| other |
77 |
50.3 |
|
| Serum levels of LDH at diagnosis |
|||
| median 306 U/l (interquartile range 185–443 U/l) |
|||
| <300 U/l |
61 |
49.2 |
|
| ≥300 U/l |
63 |
50.8 |
|
| Immunohistochemistry: |
|||
| Mcm2 immunoreactivity |
|||
| median 38% (interquartile range 29%–48%) |
|||
| <40% |
113 |
53.6 |
|
| ≥40% |
98 |
46.4 |
|
Obermann et al. BMC Cancer 2005 5:162 doi:10.1186/1471-2407-5-162 |
|||